Cisplatin feeder cell

Author: egxg

August undefined, 2024

WebWe found that expression levels of miR-302a were increased in cisplatin-treated NT2 cells. Up-regulation of miR-302a significantly increased the sensitivity of NT2 cells to cisplatin by enhancing cisplatin-induced G2/M phase arrest and the subsequent progression to … WebMay 1, 2005 · The cisplatin toxicity curve revealed a LD 50 value of 2.5 μmol/L for the ATBiva cells ( Fig. 3A ). The LD 50 for IR in ATBiva cells was found to be 0.3 Gy, consistent with published data (data not shown). Median effect analysis revealed that the lack of ATM also resulted in a reduction in the ability of IR and cisplatin to synergize ( …

MicroRNA-302a sensitizes testicular embryonal carcinoma cells to ...

WebCisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, … WebMar 15, 2003 · Cisplatin cytotoxicity was determined by the tetrazolium (MTT) assay (21). Cells (1000–8000) were plated in 150 μl of medium/well in 96-well plates (Costar, Corning Inc., Rochester, NY). After incubation overnight, cisplatin was added in various concentrations. After 72 h, 40 μl of 5 mg/ml MTT were added per well. parc financial literacy

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin …

WebJun 5, 2024 · E Cell viability of A2780 cells and resistant cells (A2780-CDDP) after were treated with cisplatin at corresponding concentrations for 48 h was detected by CCK-8 … WebTwo major issues which hamper the use of the anticancer drug cisplatin are the development of cancer cell resistance and its nephrotoxicity. One possible mechanism by which resistance is reported to develop is a reduction in … WebMay 22, 2024 · Although almost all cisplatin-resistant HNSCC cells we tested showed higher ETS-1 phosphorylation levels at T38, we found that inhibition of MEK/ERK pathways with the MEK inhibitor PD0325901 did not block this phosphorylation. parcevall hall gardens admission

Cisplatin-Resistant Cell Line - an overview ScienceDirect Topics

Differential damage and repair of DNA-adducts induced …

WebCisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Although cisplatin, … WebCisplatin is administered through a vein (intravenously or IV) as an infusion. There is no pill form of cisplatin. Cisplatin is an irritant. An irritant is a chemical that can cause … parceval messerWebSep 18, 2024 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class … おばあちゃんプレゼント実用的 90代

"WebCisplatin is a major anticancer drug that kills cancer cells by damaging their DNA. Cancer cells cope with the drug by removal of the damages with nucleotide excision repair. We have developed methods to measure cisplatin adduct formation and its repair at single-nucleotide resolution. " - Cisplatin feeder cell

Cisplatin feeder cell

Cellular responses to Cisplatin-induced DNA damage - PubMed

WebWhile the accumulation of copper and platinum do not appear to compete with each other, we did observe that cisplatin perturbs CTR1 distribution within 10 min, a far shorter incubation time than commonly employed in cellular studies of cisplatin.

Did you know?

WebFeb 11, 2024 · In this study, a cisplatin resistant gastric cancer cell line SGC7901R was determined by LC-MS/MS with increased exosomal levels of RPS3 protein. SGC7901R … WebIrinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer. The usual chemotherapy for extensive small-cell lung cancer is etoposide plus cisplatin or …

WebAug 1, 2015 · Feeder cells produce a number of growth factors and cytokines that could eventually be replaced by added recombinant proteins to the culture medium. (b) Juxtacrine and physical interactions. The presence of feeder cells is mandatory for target cells to grow, since cell–cell contact mediate juxtacrine signaling pathways and/or mechanical … WebJan 18, 2024 · Cisplatin interacts with DNA mainly in the form of Pt-d(GpG) di-adduct, which stalls cell proliferation and activates DNA damage …

WebCell-ID Cisplatin PRD018 Version 5 PRODUCT INFORMATION SHEET 1 Dispense cells into individual 15 mL tubes for each sample. 2 Centrifuge each sample at 300 x g for 5 minutes, carefully aspirate the supernatant, and mix well by gently pipetting. 3 If cells were prepared in a serum-containing medium, wash cells to remove residual protein by … WebNov 29, 2024 · Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival rate of below 10%, which is mainly due to therapy resistance.

WebJul 1, 2008 · It is known that cisplatin, which is used as a reference drug, leads to the cell cycle's arrest in most cell types in the S or G2 phases [23,24]. However, in the case of …

WebMay 16, 2011 · Abstract. Since the discovery of cisplatin more than 40 years ago and its clinical introduction in the 1970s an enormous amount of research has gone into … おばあちゃん世代服WebCisplatin (50 microM) produced time-dependent apo … The chemotherapeutic cisplatin causes renal dysfunction and renal proximal tubular cell (RPTC) apoptosis. The goal of these studies was to examine the role of p53, caspase 3, 8, and 9, and mitochondria in the signaling of cisplatin-induced apoptosis. おばあちゃんへの手紙コロナWebSep 15, 2024 · Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. … おばあちゃんプレゼント 80代食べ物WebCisplatin reacts with protein nucleophiles with which it can form covalent sulfhydryl bonds. This property makes it useful as a reagent to discriminate live cells from dead cells in … おばあちゃん上から目線WebMay 14, 2024 · Eligible patients received either pemetrexed (500 mg/m 2) and cisplatin (75 mg/m 2) by intravenous infusion on day 1 or vinorelbine (25 mg/m 2) on days 1 and 8 and cisplatin (80 mg/m 2) on day 1 by intravenous infusion. Each cycle of treatment was repeated every 3 weeks until 4 cycles were completed. おばあちゃんへの手紙コロナ例文WebThe regimen of irinotecan and cisplatin consisted of four four-week cycles of 60 mg of irinotecan per square meter of body-surface area on days 1, 8, and 15 and 60 mg of cisplatin per square... おばあちゃん倒れた嘘WebDec 7, 2024 · In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens. Methods A total of 1305 patients with previously untreated ES-SCLC were included in this study. Data from five trials were collected from the public database Project Data Sphere. おばあちゃんユーチューバー 88歳